Literature DB >> 6197381

A pigmentation-associated, differentiation antigen of human melanoma defined by a precipitating antibody in human serum.

M J Mattes, T M Thomson, L J Old, K O Lloyd.   

Abstract

Antibodies in the serum of melanoma patient AU precipitate an antigen from 125I-labelled extracts of cultured autologous melanoma cells. The antigen, which is probably not a cell surface component, is present in other pigmented melanomas but not in non-pigmented melanomas or other tumor cell types, and the amount of antigen is correlated with the degree of pigmentation. These conclusions are based on absorption experiments with 11 pigmented melanomas, 8 non-pigmented melanomas, 3 astrocytomas, 12 carcinomas of various histological types, I leukemia, 2 EB-virus-transformed B lymphocyte lines, and human erythrocytes. The antigen was also detected in cultured human melanocytes. It has a molecular weight of 70,000, an isoelectric point of pH 5.3, and it binds to concanavalin A-Sepharose. Ninety-six sera from other melanoma patients were examined and none of them precipitated this antigen. As described previously, the serum from patient AU also has antibodies to a unique (Class I) tumor antigen found only on AU melanoma cells. The pigmentation-associated, differentiation antigen and the unique antigen are clearly different in their distribution, but some relationship between these unusual antibody responses is possible.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6197381     DOI: 10.1002/ijc.2910320610

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  27 in total

1.  Tumour infiltrating lymphocytes: insights into tumour immunology and potential therapeutic implications.

Authors:  K F Yoong; D H Adams
Journal:  Clin Mol Pathol       Date:  1996-10

Review 2.  Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other".

Authors:  W W Overwijk; N P Restifo
Journal:  Crit Rev Immunol       Date:  2000       Impact factor: 2.214

Review 3.  Tumor antigens discovery: perspectives for cancer therapy.

Authors:  R F Wang
Journal:  Mol Med       Date:  1997-11       Impact factor: 6.354

4.  Monoclonal antibodies to antigens associated with transitional cell carcinoma of the human urinary bladder. I. Determination of the selectivity of six antibodies by cell ELISA and immunofluorescence.

Authors:  H Koho; S Paulie; H Ben-Aissa; I Jónsdóttir; Y Hansson; M L Lundblad; P Perlmann
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

5.  CTL activation using the natural low-affinity epitope 222-229 from tyrosinase-related protein 1 leads to tumor rejection.

Authors:  Kevin D Pavelko; Michael J Hansen; Larry R Pease
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

6.  Monoclonal antibody to an intracellular antigen images human melanoma transplants in nu/nu mice.

Authors:  S Welt; M J Mattes; R Grando; T M Thomson; R W Leonard; P B Zanzonico; R E Bigler; S Yeh; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

Review 7.  Human autologous tumor-specific T cells in malignant melanoma.

Authors:  C D Platsoucas
Journal:  Cancer Metastasis Rev       Date:  1991-06       Impact factor: 9.264

8.  Homozygous deletions within human chromosome band 9p21 in melanoma.

Authors:  J W Fountain; M Karayiorgou; M S Ernstoff; J M Kirkwood; D R Vlock; L Titus-Ernstoff; B Bouchard; S Vijayasaradhi; A N Houghton; J Lahti
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

9.  Prostate cancer health disparities: An immuno-biological perspective.

Authors:  Sanjay Kumar; Rajesh Singh; Shalie Malik; Upender Manne; Manoj Mishra
Journal:  Cancer Lett       Date:  2017-11-15       Impact factor: 8.679

10.  Immunophenotyping of melanomas for tyrosinase: implications for vaccine development.

Authors:  Y T Chen; E Stockert; S Tsang; K A Coplan; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.